Compare Novo Nordisk A/S (NVO) vs Okta, Inc. (OKTA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Okta, Inc. — how do they compare? Novo Nordisk A/S trades at $49.35 (market cap $220.53B), while Okta, Inc. trades at $141.58 (market cap $25.79B). The key difference: Novo Nordisk A/S is far larger — about 8.6× Okta, Inc.'s market cap, and Novo Nordisk A/S pays a 3.63% dividend while Okta, Inc. pays none. Which is the better fit depends on your goals.
| NVO | OKTA | |
|---|---|---|
Market Cap | $220.53B | $25.79B |
Sector | Health | Technology |
52-Week High | $71.70 | $154.62 |
52-Week Low | $35.29 | $62.93 |
Enterprise Value | $239.49B | $23.62B |
Dividend Yield | 3.63% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Okta, Inc.
Okta is a cloud-native security company that focuses on identity and access management. The San Francisco-based firm went public in 2017 and focuses on two key client stakeholder groups: workforces and customers. Okta's workforce offerings enable a company's employees to securely access its cloud-based and on-premises resources. The firm's customer offerings allow its clients' customers to securely access the client's applications.
Read more on OKTA →
